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was sent to all 14 provincial cancer centres in 2013. The survey 
included 72 questions in four different categories: 
general/demographic, pre-treatment assessment, EBRT and BT 
questions.  
Results: The response rate was 100%. Ten out of 14 centres 
treated cervical cancer patients and had a dedicated 
brachytherapy suite. All 10 centres that treated cervix cancer 
had a peer review process for quality assurance (QA). Nine 
centres had written treatment planning and delivery protocol 
and five centres used a specific plan evaluation protocol for 
organs at risk for EBRT. The standard EBRT technique was 4-field 
box in eight centres and one centre used IMRT if treating the 
para-aortic nodes simultaneously; one centre did not respond. 
The dose/fractionation scheme to the whole pelvis was 45-50 Gy 
in 1.8-2 Gy per fraction in all but one centre. Nine centres used 
image verification at some point during EBRT. All ten centres 
used HDR brachytherapy and one centre also used PDR 
brachytherapy to treat cervix cancer patients.  
Brachytherapy was performed under general anesthesia, regional 
anesthesia and conscious sedation in four, one and five centres, 
respectively. Only one centre offered interstitial brachytherapy. 
The majority of centres (eight of 10) used ultrasound image 
guidance for intrauterine applicator insertion. For treatment 
planning two centres used CT and MRI, four centres used CT only 
and four centres used orthogonal x-rays. GEC-ESTRO guidelines 
were used in three centres for target volume delineation and in 
five centres for organs at risk (OAR) dose constraints. Nine 
centres prescribed and reported dose to Point A. Volumetric dose 
prescription was performed in one centre and four centres 
reported dose to a target volume. Eight centres reported dose to 
OARs. The number of BT applicator insertions varied significantly 
between the centres ranging from one to six. The dose 
prescription was also variable ranging from 5.5 Gy to 8 Gy per 
fraction. 
Conclusions: The main findings from the survey were the 
variation in the BT dose fractionation and treatment planning 
used in the regional cancer centres while there was a general 
uniformity in peer reviewed QA, written institutional treatment 
protocol, EBRT technique, dose fractionation scheme and use of 
HDR BT across the province. This study shed light on the need to 
implement a harmonized evidence-based brachytherapy practice 
for cervical cancer in order to improve patients’ outcome across 
Ontario, Canada. 
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Purpose: The British Columbia Cancer Agency radiotherapy (RT) 
program started the Prospective Outcomes and Support Initiative 
(POSI) at all six centres in 2013 to collect and utilize patient 
reported outcomes (PROs) for patients receiving palliative intent 
RT. In 2015 it expanded to patients receiving curative intent RT, 
starting with the gynecological (gyne) tumour group. We sought 
to describe the success in expanding to non-palliative sites. 
Methods and Materials: Five validated questionnaires, the EPIC 
Bowel 2 (2002), EPIC Urinary 2 (2002), PRO-CTAE GI toxicity, 
EORTC QLQ CX24, and the EQ5DL were selected as the PROs of 
interest by the gyne tumour group. The questionnaires were 
converted to tablet format, and data was entered directly by 
patients via tablet at time of RT, and each subsequent follow up 
(FU). Some centres choose to also administer the questions 
weekly during RT, which is categorized as FU below in comparing 
scores to baseline. The results of the questionnaires were made 
available immediately to Radiation Oncologists, viewable in the 
RT electronic medical record, and in a local intranet POSI Portal. 
Descriptive Statistics were used to present accrual data and 
results of the PRO questionnaires. 
Results: From March 2015 to January 2016, 480 gyne patients 
were approached by POSI on 1007 occasions (i.e. baseline, on 
treatment, or FU), with a 97% response rate. However, not all six 
British Columbia Cancer Agency centres participated at that 
time, with Vancouver and Victoria starting in March, Abbotsford 
in July, Kelowna in August, while Surrey and Prince George have 
not yet participated. The mean (and standard deviation) scores 
of the EPIC Bowel, EPIC Urinary, PRO-CTAE GI, EORTC QLQ CX24, 
and EQ5DL were 8.9 (9.4), 6.1 (7.3), 2.9 (3.4), 2.8 (3.5), and 8.8 
(3.2), respectively, with significantly (p < 0.05) worse scores at 
FU compared to baseline for each questionnaire, except the 
EQ5DL (p = 0.62). Of the 24 patients not accrued, 29% were unfit, 
21% had not interpreter available, and 50% declined. Among 
those who declined, 33% did at baseline, 17% at first repeat 
measure, 25% at second, and 25% at the third or later repeat 
measure. Among the 189 patients who reported PRO on more 
than one time interval, 72, 37, and 80 patients repeated the PRO 
2,3, and > 3 occasions respectively to date. 
Conclusions: Expansion of POSI to collect PRO in a radical 
tumour group appears feasible, though there have been barriers 
to expansion to all six British Columbia Cancer Agency centres, 
which will be explored. Despite the use of five validated 
questionnaires totaling 49 questions, the accrual rate is 
exceptional, and appears feasible weekly during radiotherapy. 
Expansion to other radical tumour sites will be used to test if 
these results are reproducible. Future plans are to test the 
impact of providing PRO data to clinicians, and to make gyne PRO 
data available for research and quality improvement initiatives. 
 
16 
DO YOUNG WOMEN BENEFIT FROM BREAST BOOST RADIOTHERAPY 
IN THE HORMONE THERAPY ERA? 
Laura Beaton1, Elisa Chan2, Scott Tyldesley2, Lovedeep 
Gondara2, Caroline Speers2, Alan Nichol2 
1University of British Columbia, Vancouver, BC 
2British Columbia Cancer Agency, Vancouver, BC 
 
Purpose: The EORTC 22881 boost trial showed a substantial 
benefit of delivering a radiotherapy boost to the tumour bed 
(RTB) in women aged 40 years and younger, with an improvement 
in 10-year local relapse-free survival (LRFS) of 10%. However, 
this trial was carried out in an era where pre-menopausal women 
did not receive adjuvant hormone therapy (HT). We sought to 
determine how the use of HT and RTB changed in a population-
based cancer care program in response to new practice 
guidelines, and whether this had an impact on LRFS. We also set 
out to determine whether the anticipated benefit of a RTB for 
young women was observed in the era of routine HT.  
Methods and Materials: A provincial database was used to 
identify all women 40 years and younger with breast cancer that 
met the inclusion criteria of the EORTC 22881 trial: treated with 
whole breast radiotherapy after breast conserving surgery, 
margin negative (not at ink), and Stage I and II. The percentages 
of women receiving HT and RTB were compared across three Eras 
that were defined, a priori, with a three-month delay allowing 
for implementation of the practice changes: Era 1 (pre-HT, pre-
boost) January 1996-September 1998; Era 2 (HT, pre-boost) 
January 1999 - September 2001; Era 3 (HT and boost) January 
2002 - September 2004. LRFS was calculated using the Kaplan-
Meier method and the three eras compared using a log rank test. 
Factors significant at < 0.3 on univariate analysis were included 
with Era in a multivariable (MVA) Cox model. 
Results: The study included 411 patients: 130 in Era 1, 142 in Era 
2, and 139 in Era 3. The use of adjuvant HT increased over time, 
with 8% use in Era 1, 45% in Era 2 and 54% in Era 3 (p = < 0.001) 
For estrogen receptor (ER) positive cancers, HT use was higher: 
13% in Era 1, 68% in Era 2 and 82% in Era 3 (p = < 0.0001). The 
